)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sichuan Kelun Pharmaceutical
Sichuan Kelun Pharmaceutical (002422) investor relations material
Sichuan Kelun Pharmaceutical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
Q3 revenue was ¥4.274bn, up 1.93% YoY; net income attributable to shareholders was ¥339.3m, up 69.60%.
9M revenue was ¥13.113bn, down 1.24% YoY; attributable net income rose 22.18% to ¥1.467bn, while adjusted attributable net income fell 7.48% to ¥1.061bn.
Financial highlights
9M operating cash flow increased 62.46% YoY to ¥2.737bn, with settlement proceeds and higher bill discounting cited as drivers.
9M non-operating income reached ¥711.1m versus ¥4.6m a year earlier, mainly reflecting settlement proceeds; income tax expense fell 49.40% to ¥204.5m, partly due to a subsidiary tax refund.
Total assets were ¥43.032bn at Sept. 30, up 8.03% from year-end; parent-attributable equity was ¥25.993bn, up 7.30%.
Key financial ratios and metrics
Basic and diluted EPS were ¥0.21 in Q3, up 75.00% YoY; 9M EPS was ¥0.92, up 22.67%.
Weighted average ROE was 1.32% for Q3, up 0.49 percentage points YoY, and 5.91% for 9M, up 0.73 percentage points.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sichuan Kelun Pharmaceutical
- Net profit rose 12.7% to ¥1.13 billion as innovative drug sales offset revenue decline.002422
H1 2026 - Q1 2026 saw lower revenue and profit but strong R&D and new drug approvals.002422Q1 2026
- 2025 revenue rose 6.5% to RMB 2.06B, with robust R&D and commercialization expansion.002422H2 2025
- ADC innovation and global partnerships drive growth, with multiple approvals and expanding indications.00242244th Annual J.P. Morgan Healthcare Conference
- Q3 profit and revenue dropped significantly, but new drug approvals and financing boost outlook.002422Q3 2025
- Revenue and profit fell sharply, but first-year commercialization and R&D remain strong.002422H1 2025
- Net profit up 28.2% to ¥1.80B on 9.5% revenue growth, with strong API and R&D gains.002422H1 2024
- Net profit surged 19.88% in Q3 2024, driven by innovation and capital optimization.002422Q3 2024
- Net profit surged 19.53% to ¥2.94 billion on record revenue and strong innovation output.002422H2 2024
Next Sichuan Kelun Pharmaceutical earnings date
H2 20262 Apr, 2027
Sichuan Kelun Pharmaceutical
Next Sichuan Kelun Pharmaceutical earnings date
H2 20262 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sichuan Kelun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio includes intravenous (IV) solutions, antibiotics, oncology treatments, and other specialty drugs, serving hospitals, healthcare facilities, and pharmacies. Sichuan Kelun focuses on developing generic and innovative drugs to address various therapeutic areas, including infectious diseases, oncology, and chronic conditions. In addition to pharmaceuticals, the company is involved in biotechnology research to expand its product offerings. The company is headquartered in Chengdu, China, and its shares are listed on the Shenzhen Stock Exchange.